Fusen Pharmaceutical (1652) Announces Selection in Eleventh Batch of National Centralised Medicines Procurement

Bulletin Express
10/30

Fusen Pharmaceutical Company Limited (Stock Code: 1652) announced on 30 October 2025 that one of its products, Metformin Empagliflozin Tablets (I) (metformin hydrochloride 500 mg and empagliflozin 5 mg), was successfully selected in the tender results of the eleventh batch of the National Centralised Medicines Procurement in China on 27 October 2025.

The announcement indicates that the update is made on a voluntary basis to inform shareholders and potential investors of recent business developments.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10